Document is current
Any future updates will be listed below
-
Authors
Watson, Brianna R. https://orcid.org/0000-0001-6540-5330
Paul, Biplab
Rahman, Raza Ur
Amir-Zilberstein, Liat
Segerstolpe, Åsa
Epstein, Eliana T.
Murphy, Shane
Geistlinger, Ludwig
Lee, Tyrone https://orcid.org/0009-0008-7750-0448
Shih, Angela
Deguine, Jacques https://orcid.org/0000-0001-9218-3040
Xavier, Ramnik J. https://orcid.org/0000-0002-5630-5167
Moffitt, Jeffrey R. https://orcid.org/0000-0002-3836-3101
Mullen, Alan C. https://orcid.org/0000-0002-4096-3106
-
Funding
Funding for this research was provided by:
Chan Zuckerberg Initiative Seed Project
- License Information
-
More Information
Article History
Received: 5 September 2024
Accepted: 9 December 2024
First Online: 2 January 2025
Competing interests
: R.J.X. is a co-founder of Celsius Therapeutics and Jnana Therapeutics, board director at MoonLake Immunotherapeutics, and consultant to Nestlé. J.R.M is a co-founder of, stake-holder in, and advisor for Vizgen. J.R.M. is an inventor on patents associated with MERFISH applied for on his behalf by Harvard University and Boston Children’s Hospital. J.R.M.‘s interests were reviewed and are managed by Boston Children’s Hospital in accordance with their conflict-of-interest policies. J.R.M. has received research funding from Merck for unrelated projects. A.C.M. has received research funding from Boehringer Ingelheim and GlaxoSmithKline for unrelated projects. The remaining authors declare no competing interests.
